Immunology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      ANKYLOSING SPONDYLITIS

      Once-daily oral treatment for your adult patients with active ankylosing spondylitis1

      One dose, one tablet, once a day

      RINVOQ package
      div

      Dosing recommendations1

      calendar
      • The recommended dose of RINVOQ is one 15-mg tablet once a day, with or without meals
      tablets
      • Tablets should be swallowed whole, and should not be split, crushed, or chewed
      clock
      • RINVOQ may be taken at any time of the day; patients may find it easier to take RINVOQ at the same time every day to help them remember to take it
      clock
      • Consideration should be given to discontinuing treatment in patients with ankylosing spondylitis who have shown no clinical response after 16 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.

      Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.

      transition
      transition

      Reference

      1. RINVOQ SmPC.
      RINVOQ PRESCRIBING INFORMATION
      ADALIMUMAB PRESCRIBING INFORMATION

      UK-UPAD-230034. Date of preparation: March 2023

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on [email protected]